TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04806763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Menicon Z Night
Description: To assess the use of Menicon Z Night contact lenses for reducing myopia progression in children

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Distance, single-vision glasses were used as control
Study: NCT01873391

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic hysteroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic hysteroscopy
Study: NCT00754559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8mg/kg iv every 4 weeks
Study: NCT03576820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive intranasal lidocaine via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Baseline pain score and associated migraine symptoms (such as nausea, vomiting, photophobia, and phonophobia) will be recorded for each subject. Subjects will then receive 0.9% sodium chloride solution via atomizer. Pain scores will be reassessed at 5, 10, and 20 minutes. Improvement in associated symptoms will be reassessed at 20 minutes.
Study: NCT03890107

Intervention type: DEVICE
Intervention: OtoSight Middle Ear Scope
Description: OtoSight imaging using a near-infrared laser
Study: NCT03599297

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral synchronous simultaneous stone surgery
Description: Patients undergoing Bilateral synchronous simultaneous stone surgery (one kidney undergoing percutaneous nephrolithotomy, other kidney undergoing ureteroscopy at the same time in a single patient)
Study: NCT02100644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine tablets 25/100 mg
Description: Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG\&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
Study: NCT04107285

Intervention type: BEHAVIORAL
Intervention: neurocognitive evaluations
Description: The test battery consists of validated and reliable measures of attention, executive functions and memory.

Intervention type: DIAGNOSTIC_TEST
Intervention: brain MRIs
Description: Patients will undergo baseline and follow-up research MRIs in the same scanner at MSKCC (3 Tesla scanner (GE, Discovery 750W, USA) with a GEM HNU 24-channel head coil) (total scan duration=15 minutes).

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected at each time point (Day -1, day 0, day 1, day 3, day 5, day 7, day 10, day of neurotoxicity onset, and 3-4 months post- CART).
Study: NCT00540761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI imaging
Description: Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI imaging
Description: Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.
Study: NCT03773055

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPC-06
Description: Patients will receive once a day for 7 days.
Study: NCT02501811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSC)
Description: 15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSC)
Description: 15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: c-kit+ cells
Description: 15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: c-kit+ cells
Description: 15 transendocardial injections of 0.4ml c-kit+ cells administered to the left ventricle via NOGA Myostar injection catheter (single procedure)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Plasmalyte A)
Description: 15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
Study: NCT02997202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT03615664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine (B) 90 mg/m2 i.v. day 1, 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (G) 800 mg/m2 i.v. day 1, 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (D) 40 mg i.v./p.o. day 1,2,3,4

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: PET scan/CT must be performed after first 2 courses of BGD treatment. Results evaluation:~* in case of a CMR/CR or PMR/PR, ASCT must be performed within 3 months after the end of BGD treatment~* in case of SMD - exclusion from the trial~* in case of PMD - exclusion from the trial

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant
Description: Must be performed within 3 months after the end of BGD treatment.~When it is not possible to perform ASCT, despite CMR or PMR response, within 3 months after second course of BGD treatment, it is permissible to extend the therapy up to 4 cycles. PET scan/CT must be repeated before performing ASCT.
Study: NCT02359968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: radiochemotherapy before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CarboP-pacliT
Description: radiochemotherapy before surgery
Study: NCT03248479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered according to region-specific drug labeling either subcutaneously or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered according to region-specific drug labeling either subcutaneously or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered according to region-specific drug labeling either subcutaneously or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered according to region-specific drug labeling either subcutaneously or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered according to region-specific drug labeling either subcutaneously or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered according to region-specific drug labeling either subcutaneously or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered according to region-specific drug labeling either subcutaneously or intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered according to region-specific drug labeling either subcutaneously or intravenously
Study: NCT02531542

Intervention type: DEVICE
Group type: OTHER
Intervention: Echocardiography according to the READ method.
Description: * Echocardiography will be performed before any therapy is initiated by a fully trained operator, according to the READ method. The results of this ultrasound will not be communicated to the clinician managing the patient in the emergency room.~* A blood sample will be taken during the routine work-up for centralized evaluation of NT-proBNP levels.
Study: NCT00001481

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol
Description: To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Progesterone
Description: To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: To determine whether it is abrupt withdrawal or prolonged exposure to gonadal steroids that is associated with PPD.
Study: NCT04250493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical characteristics of AMS patients
Description: Severity and progression of motor disorders assessed by the UMSARS scale, severity of dysautonomia assessed by the COMPASS31 scale ; quality of life questionnaire (AMS-Qol) for the level of difficulty experienced by the patient (on activities such as : move; walk; maintain balance; talk; feed)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brain Magnetic Resonance Imaging (MRI)
Description: Brain Magnetic Resonance Imaging (MRI) : putamen imaging, bridge and cerebellum; white substance hypersignals volume

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain Magnetic Resonance Imaging (MRI)
Description: Brain Magnetic Resonance Imaging (MRI) : putamen imaging, bridge and cerebellum; white substance hypersignals volume

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: Optional blood sampling for the constitution of a biological collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Optional blood sampling for the constitution of a biological collection
Study: NCT03083951

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete mesocolon excision
Description: Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric vein and a high tie ligation of the inferior mesenteric artery (complete mesocolon excision)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional locoregional lymphadenectomy
Description: Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric artery and a high tie ligation of the inferior mesenteric artery with or without section of inferior mesenteric vein.
Study: NCT01918215

Intervention type: DEVICE
Group type: OTHER
Intervention: ICD

Intervention type: DEVICE
Group type: OTHER
Intervention: ILR
Study: NCT03471676

Intervention type: OTHER
Intervention: Muscular oximetry
Description: 6 minutes walking test performed in the routine medical care with muscle oximetry recording
Study: NCT04284917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carglumic Acid (Carbaglu®)
Description: A. Study period: 24 months; treatment period: 12 months.~B. Patients will receive Carglumic Acid (Carbaglu®) 50 mg/kg/day in addition to standard therapy (protein restricted diet, L-carnitine, metronidazole and vitamin B12)~C. Patients need to regularly come back for follow up examination on Day 0, month 3, month 6, and month 12. (Check Plasma Amino Acid Analysis, Ammonia, acylcarnitine profile, Urinary organic acid analysis.)~D. Patients should report any adverse event that occur during treatment period.~E. Patients' number of emergency visits due to hyperammonemia, ammonia level, acylcarnitine, urinary organic acid analysis, plasma amino acid analysis will be recorded during treatment period.
Study: NCT00800033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic exercise training
Description: Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pulse based diet
Description: Two pulse-based meals per day (lentils, beans, chickpeas, or peas) for 2 months, followed by 1-month washout and then a normal diet for 2 months (order of diets is randomized)
Study: NCT05500131

Intervention type: BEHAVIORAL
Intervention: Observation
Description: Ankle joint dorsiflexion was evaluated with the Weight-bearing lunge test through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). Subjects were instructed to try to bring the knee to touch the metal rod (initially placed at a distance of 10 cm) without lifting the heel off the ground. The distance achieved was recorded in centimeters.~Single-leg squat test was analyzed through the Leg Motion system (LegMotion, your MOtion®, Albacete, Spain). It consists of performing a monopodial squat to test dynamic knee valgus. They were to perform a single-leg squat to 30° knee flexion. The knee was considered to be aligned if the patella was over the second toe.
Study: NCT01724320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX008
Description: OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
Study: NCT00815516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micafungin
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amphotericin B deoxycholate
Description: Administered by intravenous infusion
Study: NCT02752555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antioxidant (l-cratinine) + modifiable lifestyle factors
Description: All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.
Study: NCT00865462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrika Bupropion 150 mg XL Tablet, single dose
Description: A: Experimental Subjects received Abrika formulated products under fed conditions
Study: NCT00950300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m\^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m\^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide, 500 mg/m\^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Participants will receive cyclophosphamide, 500 mg/m\^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Participants will receive docetaxel, 75 mg/m\^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel, 75 mg/m\^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Participants will receive epirubicin, 75 mg/m\^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Participants will receive epirubicin, 75 mg/m\^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Study: NCT04202094

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical examination
Description: A physical examination to measure the patients' weight, height, body mass index, blood pressure and testicular volume using a Prader orchidometer and to determine the patients' Tanner stage (secondary sexual development).
Study: NCT00950300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin IV [trastuzumab]
Description: Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin SC [trastuzumab]
Description: Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
Study: NCT00865462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wellbutrin XL® 150 mg Tablet, single dose
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
Study: NCT01376596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy based intervention immediately
Description: This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring: Identify negative thoughts that occur before, during, or after anxiety-provoking situations; Evaluate the accuracy of their thoughts in the light of data derived from Socratic questioning or as a result of so-called behavioral experiments; and derive rational alternative thoughts based on the acquired information; iii) Exposure component, which focuses on the collection of information that will allow patients to revise their judgments about the degree of risk to which they are exposed in feared situations, challenge their dysfunctional beliefs about the self relative to the illness and their self-efficacy (social status related), and iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait list
Description: The group receiving treatment as usual (TAU) will be put on a wait list to receive the CBT intervention at the end of the experimental group, the one receiving the intervention immediately
Study: NCT03968328

Intervention type: OTHER
Intervention: Interview
Description: Take part in interview

Intervention type: OTHER
Intervention: Survey Administration
Description: Respond to survey
Study: NCT01959828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IK-3001
Study: NCT00516295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT03146143

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrafiltration
Description: ultrafiltration after cardiopulmonary bypass
Study: NCT02013050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGX942

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01252758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol sufate DPI (TBS-7) dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol sufate DPI (TBS-7) dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol sufate DPI (TBS-7) dose 3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Study: NCT03917758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: Start of the treatment with SGLT2i.
Study: NCT03044873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.